The newly-released Public Summary Document shows the PBAC acknowledging the efficacy and strong support for the listing of Sanofi's DUPIXENT (dupilumab) for severe atopic dermatitis but also its focus on the potential mix of new and continuing patients. …
Latest Video
New Stories
-
COVID-19 vaccine manufacturing, supply and administration programs
January 22, 2021 - - Latest News -
Bionomics-BMS combination completes trial treatment phase
January 22, 2021 - - Australian Biotech -
Almac Group survey reveals pandemic impact on clinical trial activity
January 22, 2021 - -
Industry slams last minute Trump move to cut medicine coverage
January 22, 2021 - -
Queensland research institute in new cell therapy trial
January 21, 2021 - - Latest News -
This is what being 'among the first in the world' looks like
January 21, 2021 - - Latest News -
Hundreds of exemptions from active ingredient prescribing
January 21, 2021 - - Latest News